07.01.2013 Views

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

Sorted By Test Name - Mayo Medical Laboratories

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

FIFAF<br />

91181<br />

FSAGA<br />

90047<br />

X-linked disorder, it occurs almost exclusively in males with an estimated incidence of 1 in 100,000 male<br />

births (though symptomatic carrier females have been reported). Treatment options include hematopoietic<br />

stem cell transplantation and/or enzyme replacement therapy. A diagnostic workup in an individual with<br />

MPS II typically demonstrates elevated levels of urinary GAGs and increased amounts of both dermatan<br />

and heparan sulfate detected on thin-layer chromatography. Reduced or absent activity of IDS in<br />

fibroblasts, leukocytes plasma, and/or serum can confirm a diagnosis of MPS II; however, enzymatic<br />

testing is not reliable to detect carriers. Molecular sequence analysis of the IDS gene allows for detection<br />

of the disease-causing mutation in affected patients and subsequent carrier detection in female relatives.<br />

Currently, no clear genotype-phenotype correlations have been established.<br />

Useful For: Diagnosis of mucopolysaccharidosis II (MPS II, Hunter syndrome)<br />

Interpretation: Values near zero suggest mucopolysaccharidosis II. Values above the reference range<br />

are not clinically significant.<br />

Reference Values:<br />

0.15-0.86 nmol/hour/mg<br />

Clinical References: 1. Martin R, Beck M, Eng C, et al: Recognition and diagnosis of<br />

mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008;121(2):e377-86 2. Wraith JE, Scarpa M,<br />

Beck M, et al: Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations<br />

for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167(3):266-277 3. Wasteson<br />

A, Neufeld EF: Iduronate sulfatase from human plasma. Meth Enzymol 1982;83:573-578 4. Enns GM,<br />

Steiner RD, Cowan TM: Lysosomal Disorders. In Pediatric Endocrinology and Inborn Errors of<br />

Metabolism. Edited by K Sarafoglou, GF Hoffmann, KS Roth, New York, McGraw-Hill <strong>Medical</strong><br />

Division, 2009, pp 732<br />

IgA Fibronectin Aggregates, ELISA<br />

Reference Values:<br />

REFERENCE RANGE: < 3.0 EIA Units<br />

INTERPRETIVE CRITERIA:<br />

< 3.0 Aggregates Not Detected<br />

> or = 3.0 Aggregates Detected<br />

Aggregates consisting of IgA complexed with fibronectin are<br />

found in sera of most patients with IgA nephropathy and<br />

patients with Henoch-Schonlein purpura. Detection of these<br />

aggregates is based on their specific attachment to a<br />

fragment of Type I collagen.<br />

<strong>Test</strong> Performed by: Focus Diagnostics, Inc.<br />

5785 Corporate Avenue<br />

Cypress, CA 90630-4750<br />

IgA Salivary, RID<br />

Reference Values:<br />

REFERENCE RANGE: 6.2-14.5 mg/dL<br />

Decreased salivary IgA may be present in children with recurrent<br />

upper respiratory infection, selective IgA deficiency and occasional<br />

individuals with food allergies.<br />

This assay was performed using a kit labeled "For Research Use<br />

Only" by the kit manufacturer. The kitâ€s performance characteristics<br />

have been established and validated by FOCUS TECHNOLOGIES<br />

Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or <strong>Mayo</strong><strong>Medical</strong><strong>Laboratories</strong>.com Page 998

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!